A novel 4-oxo-2(E)-nonenal-derived modification to angiotensin II: Oxidative decarboxylation of N-terminal aspartic acid

Chemical Research in Toxicology

Volumn 21, Issue 12, 2008, Pages 2237-2244

  Seon, Hwa Lee ^a   Goto, Takaaki ^a   Oe, Tomoyuki ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 OXO 2 NONENAL; ALDEHYDE DERIVATIVE; AMIDE; ANGIOTENSIN II; ANGIOTENSIN II DERIVATIVE; ASPARTIC ACID; HYDROGEN; KETONE; PYRUVIC ACID DERIVATIVE; SCHIFF BASE; SODIUM BOROHYDRIDE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CHEMICAL MODIFICATION; CONCENTRATION (PARAMETERS); DECARBOXYLATION; HYDROLYSIS; LIPID PEROXIDATION; PROTEIN STRUCTURE; REDUCTION; STRUCTURE ANALYSIS;

ALDEHYDES; ANGIOTENSIN II; ASPARTIC ACID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DECARBOXYLATION; HUMANS; OXIDATION-REDUCTION; PYRUVATES; SCHIFF BASES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 58149090525     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx800316v     Document Type: Article

References (35)

1. Ames, B. N., Shigenaga, M. K., and Hagen, T. M. (1993) Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl. Acad. Sci. U.S.A. 90, 7915-7922.
2. Lee, S. H., Oe, T., and Blair, I. A. (2001) Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. Science 292, 2083-2086.
3. Benedetti, A., Comporti, M., and Esterbauer, H. (1980) Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids. Biochim. Biophys. Acta 620, 281-296.
4. Esterbauer, H., Schaur, R. J., and Zollner, H. (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radical Biol. Med. 11, 81-128.
5. Rauli, S., Puppo, M. D., Magni, F., and Kienle, M. G. (1998) Validation of malondialdehyde and 4-hydroxy-2-trans-nonenal measurement in plasma by NICI-GC-MS. J. Biochem. 123, 918-923.
6. Spies-Martin, D., Sommerburg, O., Langhans, C. D., and Leichsenring, M. (2002) M easurement of 4-hydroxynonenal in small volume blood plasma samples: modification of a gas chromatographic-mass spectrometric method for clinical settings. J. Chromatogr. B 774, 231-239.
7. Uchida, K. (2003) 4-Hydroxy-2-nonenal: A product and mediator of oxidative stress. Prog. Lipid Res. 42, 318-343.
8. Leonarduzzi, G., Robbesyn, F., and Poli, G. (2004) Signaling kinases modulated by 4-hydroxynonenal. Free Radical Biol. Med. 37, 1694-1702.
9. 2ethenodeoxyguanosine as a potential marker for DNA adduct formation by trans-4-hydroxy-2- nonenal. Cancer Res. 48, 320-323.
10. Nadkarni, D. V., and Sayre, L. M. (1995) Structural definition of early lysine and histidine adduction chemistry of 4-hydroxynonenal. Chem. Res. Toxicol. 8, 284-291.
11. Jian, W., Lee, S. H., Mesaros, C., Oe, T., Silva Elipe, M. V., and Blair, I. A. (2007) A novel 4-oxo-2(E)-nonenal-derived endogenous thiadiazabicyclo glutathione adduct formed during cellular oxidative stress. Chem. Res. Toxicol. 20, 1008-1018.
12. Lee, S. H., and Blair, I. A. (2000) Characterization of 4-oxo-2-nonenal as a novel product of lipid peroxidation. Chem. Res. Toxicol. 13, 698-702.
13. Rindgen, D., Nakajima, M., Wehrli, S., Xu, K., and Blair, I. A. (1999) Covalent modifications to 2′-deoxyguanosine by 4-oxo-2-nonenal, a novel product of lipid peroxidation. Chem. Res. Toxicol. 12, 1195-1204.
14. Lee, S. H., Rindgen, D., Bible, R. H., Jr., Hajdu, E., and Blair, I. A. (2000) Characterization of 2′-deoxyadenosine adducts derived from 4-oxo-2-nonenal, a novel product of lipid peroxidation. Chem. Res. Toxicol. 13, 565-574.
15. Pollack, M., Oe, T., Lee, S. H., Silva Elipe, M. V., Arison, B. H., and Blair, I. A. (2003) Characterization of 2′-deoxycytidine adducts derived from 4-oxo-2-nonenal, a novel lipid peroxidation product. Chem. Res. Toxicol. 16, 893-900.
16. Doorn, J. A., and Petersen, D. R. (2002) Covalent modification of amino acid nucleophiles by the lipid peroxidation products 4-hydroxy-2-nonenal and 4-oxo-2-nonenal. Chem. Res. Toxicol. 15, 1445-1450.
17. Zhang, W.-H., Liu, J., Xu, G., Yuan, Q., and Sayre, L. M. (2003) Model studies on protein side-chain modification by 4-oxo-2-nonenal. Chem. Res. Toxicol. 16, 512-523.
18. Oe, T., Lee, S. H., Silva Elipe, M. V., Arison, B. H., and Blair, I. A. (2003) A novel lipid hydroperoxide derived modification to arginine. Chem. Res. Toxicol. 16, 1598-1605.
19. Oe, T., Arora, J. S., Lee, S. H., and Blair, I. A. (2003) A novel lipid hydroperoxide-derived cyclic covalent modification to histone H4. J. Biol. Chem. 278, 42098-42105.
20. Yocum, A. K., Oe, T., Yergey, A. L., and Blair, I. A. (2005) Novel lipid hydroperoxide-derived hemoglobin histidine adducts as biomarkers of oxidative stress. J. Mass Spectrom. 40, 754-764.
21. Zhu, X., and Sayre, L. M. (2007) Long-lived 4-oxo-2-enal-derived apparent lysine Michael adducts are actually the isomeric 4-ketoamides. Chem. Res. Toxicol. 20, 165-170.
22. Suzuki, H., Frank, G. D., Utsunomiya, H., Higuchi, S., and Eguchi, S. (2006) Current understanding of the mechanism and role of ROS in angiotensin II signal transduction. Curr. Pharm. Biotechnol. 7, 81-86.
23. Griendling, K. K., and Ushio-Fukai, M. (2000) Reactive oxygen species as mediators of angiotensin II signaling. Regul. Pept. 91, 21-27.
24. Ohtsu, H., Frank, G. D., Utsunomiya, H., and Eguchi, S. (2005) Redox-dependent protein kinase regulation by angiotensin II: Mechanistic insights and its pathophysiology. Antioxid. Redox Signaling 7, 1315-1326.
25. Gilmore, J. M., Scheck, R. A., Esser-Kahn, A. P., Joshi, N. S., and Francis, M. B. (2006) N-Terminal protein modification through a biomimetic transamination reaction. Angew. Chem., Int. Ed. 45, 5307-5311.
26. Kim, M. S., Jeon, J. W., and Suh, J. (2005) Angiotensin-cleaving catalysts: Conversion of N-terminal aspartate to pyruvate through oxidative decarboxylation catalyzed by Co(III)cyclen. J. Biol. Inorg. Chem. 10, 364-372.
27. Wei, E. K., Giovannucci, E., Selhub, J., Fuchs, C. S., Hankinson, S. E., and Ma, J. (2005) Plasma vitamin B6 and the risk of colorectal cancer and adenoma in women. J. Natl. Cancer Inst. 97, 684-692.
28. Cesari, M., Rossi, G. P., and Pessina, A. C. (2002) Biological properties of the angiotensin peptides other than angiotensin II: Implications for hypertension and cardiovascular diseases. J. Hypertens. 20, 793-799.
29. Wright, J. W., Tamura-Myers, E., Wilson, W. L., Roques, B. P., Llorens-Cortes, C., Speth, R. C., and Harding, J. W. (2003) Conversion of brain angiotensin II to angiotensin III is critical for pressor response in rats. Am. J. Physiol. 284, R725-R733.
30. Jankowski, V., Vanholder, R., van der Giet, M., Tölle, M., Karadogan, S., Gobom, J., Furkert, J., Oksche, A., Krause, E., Tran, T. N., Tepel, M., Schuchardt, M., Schlüter, H., Wiedon, A., Beyermann, M., Bader, M., Todiras, M., Zidek, W., and Jankowski, J. (2007) Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler., Thromb., Vasc. Biol. 27, 297-302.
31. Matsui, T., Tamaya, K., Matsumoto, K., Osajima, Y., Uezono, K., and Kawasaki, T. (1999) Plasma concentrations of angiotensin metabolites in young male normotensive and mild hypertensive subjects. Hypertens. Res. 22, 273-277.
32. Kobori, H., Nangaku, M., Navar, L. G., and Nishiyama, A. (2007) The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 59, 251-287.
33. 2, HOONO)-evaluation by mass spectrometry. Eur. J. Biochem. 253, 146-153.
34. Lee, S. J., Lee, J. R., Kim, Y. H., Park, Y. S., Park, S. I., Park, H. S., and Kim, K. P. (2007) Investigation of tyrosine nitration and nitrosylation of angiotensin II and bovine serum albumin with electrospray ionization mass spectrometry. Rapid Commun. Mass Spectrom. 21, 2797-2804.
35. Uchida, K., and Kawakishi, S. (1990) Site-specific oxidation of angiotensin I by copper(II) and L-ascorbate: Conversion of histidine residues to 2-imidazolones. Arch. Biochem. Biophys. 283, 20-26.